Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease
Authors
Keywords
-
Journal
World Journal of Gastrointestinal Oncology
Volume 13, Issue 8, Pages 772-798
Publisher
Baishideng Publishing Group Inc.
Online
2021-08-12
DOI
10.4251/wjgo.v13.i8.772
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis
- (2021) Natasha Klemm et al. Clinics and Research in Hepatology and Gastroenterology
- Checkpoint Inhibitor–Induced Colitis
- (2020) Emanuelle Bellaguarda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1 treated patients in the Dutch Melanoma Treatment Registry
- (2020) Rik J. Verheijden et al. CLINICAL CANCER RESEARCH
- Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: a Systematic Review
- (2020) Michael Collins et al. Clinical Gastroenterology and Hepatology
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020
- (2020) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy
- (2020) Tenglong Tang et al. Clinical Colorectal Cancer
- Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
- (2020) Sarina A. Piha-Paul et al. INTERNATIONAL JOURNAL OF CANCER
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy
- (2020) Kaustav P Shah et al. Cancer Immunology Research
- Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
- (2020) Meghan J Mooradian et al. Journal for ImmunoTherapy of Cancer
- Risk of Gastrointestinal Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Systematic Review and Meta-Analysis
- (2020) Wenhan Yang et al. Frontiers in Oncology
- Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
- (2020) Shilpa Grover et al. CANCER
- Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
- (2020) Adrienne M. Luoma et al. CELL
- Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series
- (2020) Manuel B. Braga Neto et al. Clinical Gastroenterology and Hepatology
- Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis
- (2020) Yukie Hayashi et al. DIGESTIVE DISEASES AND SCIENCES
- Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system
- (2020) Yingying Hu et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy
- (2020) Khashayar Esfahani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers
- (2020) Oliver Klein et al. JAMA Oncology
- Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
- (2020) Michelle Coureau et al. Frontiers in Medicine
- Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma
- (2020) David M Favara et al. ESMO Open
- AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor (ICI) Colitis and Hepatitis: Expert Review
- (2020) Michael Dougan et al. GASTROENTEROLOGY
- Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens
- (2020) Jiannan Yao et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
- (2020) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy
- (2020) Marc T Roth et al. Expert Review of Anticancer Therapy
- Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
- (2020) Thierry André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma
- (2019) Hamzah Abu-Sbeih et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Complete response of metastatic melanoma in a patient with Crohn’s disease simultaneously receiving anti-α4β7 and anti-PD1 antibodies
- (2019) Christopher C. Frohne et al. Journal for ImmunoTherapy of Cancer
- Efficacy and safety of immune checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer: a systematic review and meta-analysis
- (2019) Cong Chen et al. OncoImmunology
- To treat or not to treat: Patient exclusion in immune oncology clinical trials due to preexisting autoimmune disease
- (2019) Morgan Pantuck et al. CANCER
- Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control
- (2019) Michael S. Hughes et al. Cancer Medicine
- Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- (2019) Eileen M. O’Reilly et al. JAMA Oncology
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Cancer and Preexisting Autoimmune Disease: A Nationwide Multicenter Cohort Study
- (2019) Alice Tison et al. Arthritis & Rheumatology
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
- (2019) Ken Masuda et al. BMC CANCER
- Immune checkpoint inhibitor‐induced diarrhea: Clinicopathological study of 11 patients
- (2019) Shunichi Yanai et al. Digestive Endoscopy
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164
- (2019) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors
- (2019) Koichi Miyahara et al. DIGESTION
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease
- (2019) Hamzah Abu-Sbeih et al. JOURNAL OF CLINICAL ONCOLOGY
- Low Rates of Dermatologic Care and Skin Cancer Screening Among Inflammatory Bowel Disease Patients
- (2018) Alyce Anderson et al. DIGESTIVE DISEASES AND SCIENCES
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy
- (2018) Parul Tandon et al. JOURNAL OF IMMUNOTHERAPY
- Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Cancer Drugs Approved Based on Biomarkers and Not Tumor Type—FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers
- (2018) Vinay Prasad et al. JAMA Oncology
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson
- (2018) Yinghong Wang et al. Journal for ImmunoTherapy of Cancer
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- Checkpoint inhibitor colitis
- (2018) Spyros I. Siakavellas et al. CURRENT OPINION IN GASTROENTEROLOGY
- Enterocolitis due to immune checkpoint inhibitors: a systematic review
- (2018) Emilie Soularue et al. GUT
- Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials
- (2018) Bo Zhang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
- (2018) Yelena Y. Janjigian et al. JOURNAL OF CLINICAL ONCOLOGY
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
- (2018) N Boku et al. ANNALS OF ONCOLOGY
- Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
- (2018) Yinghong Wang et al. NATURE MEDICINE
- Clinical characterization of colitis arising from anti-PD-1 based therapy
- (2018) Daniel Y Wang et al. OncoImmunology
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
- (2018) Hamzah Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer
- Understanding and Preventing the Global Increase of Inflammatory Bowel Disease
- (2017) Gilaad G. Kaplan et al. GASTROENTEROLOGY
- Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease
- (2017) Sushil K. Garg et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies
- (2017) Siew C Ng et al. LANCET
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
- (2017) Paolo A Ascierto et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Inflammatory bowel disease caused by primary immunodeficiencies-Clinical presentations, review of literature, and proposal of a rational diagnostic algorithm
- (2017) Daniel Tegtmeyer et al. PEDIATRIC ALLERGY AND IMMUNOLOGY
- T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
- (2017) Enfu Hui et al. SCIENCE
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis
- (2017) Daniel Y. Wang et al. OncoImmunology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Anti-PD1-induced collagenous colitis in a melanoma patient
- (2016) Barouyr Baroudjian et al. MELANOMA RESEARCH
- Fulminant Myocarditis with Combination Immune Checkpoint Blockade
- (2016) Douglas B. Johnson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment
- (2016) Jordan E Axelrad et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Epidemiology and risk factors for IBD
- (2015) Ashwin N. Ananthakrishnan Nature Reviews Gastroenterology & Hepatology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Protective effects of Fc-fused PD-L1 on two different animal models of colitis
- (2014) Mi-Young Song et al. GUT
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
- (2012) Tadashi Yokosuka et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma
- (2010) C. Ralph et al. CLINICAL CANCER RESEARCH
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- (2010) Richard E. Royal et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation